Key Takeaways From Becton Dickinson Analyst Ratings

Throughout the last three months, 5 analysts have evaluated Becton Dickinson BDX, offering a diverse set of opinions from bullish to bearish.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $281.2, a high estimate of $312.00, and a low estimate of $255.00. This current average has decreased by 0.02% from the previous average price target of $281.25.

Diving into Analyst Ratings: An In-Depth Exploration

An in-depth analysis of recent analyst actions unveils how financial experts perceive Becton Dickinson. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Becton Dickinson. This offers insight into analysts' perspectives on the current state of the company.
• Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Becton Dickinson compared to the broader market.
• Price Targets: Understanding forecasts, analysts offer estimates for Becton Dickinson's future value. Examining the current and prior targets provides insight into analysts' changing expectations.

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Becton Dickinson's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Becton Dickinson analyst ratings.

Discovering Becton Dickinson: A Closer Look

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures pre-filled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2023 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.

Financial Milestones: Becton Dickinson's Journey

Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.

Revenue Growth: Over the 3 months period, Becton Dickinson showcased positive performance, achieving a revenue growth rate of 4.65% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Becton Dickinson's net margin is impressive, surpassing industry averages. With a net margin of 10.64%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): Becton Dickinson's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.11%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): Becton Dickinson's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.01%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: Becton Dickinson's debt-to-equity ratio is below the industry average at 0.7, reflecting a lower dependency on debt financing and a more conservative financial approach.

How Are Analyst Ratings Determined?

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

This article was generated by Benzinga's automated content engine and reviewed by an editor.